Minor Cannabinoids: What Is Known About CBG, CBN and CBC

The evidence differs sharply by compound. CBG has been studied in one small, acute, double-blind, placebo-controlled crossover trial involving 34 healthy adults.

By Cannible Editorial

2026-08-06

The evidence differs sharply by compound. CBG has been studied in one small, acute, double-blind, placebo-controlled crossover trial involving 34 healthy adults. CBN has objective sleep findings from a rat study, while the supplied evidence on CBC consists of a review and preliminary research rather than a reported controlled human trial. These findings should not be combined: evidence for one cannabinoid does not establish effects or safety for another. 1 2 3

This article is general information, not individualized medical advice. A personal decision about a cannabinoid, medication, symptom, or possible interaction should be discussed with a clinician, pharmacist, or other qualified professional.

CBG: one small acute human study

Controlled human evidence for CBG is limited but does exist. In a double-blind, placebo-controlled crossover field trial, 34 healthy adults received either 20 mg of hemp-derived CBG or placebo tincture in separate sessions one week apart. The sessions were conducted remotely, with participants completing ratings and tests before and after administration. 1

In that single acute study, CBG was associated with greater overall reductions in anxiety and reductions in stress after participants ingested it, compared with placebo. CBG also improved verbal-memory performance relative to placebo, and the study found no evidence of subjective drug effects or impairment. These are controlled human findings in healthy adults under the study’s conditions; they do not establish long-term effects, treatment of an anxiety disorder, or results for other populations or products. 1

Separate pharmacology research describes CBG as acting on several biological targets, including cannabinoid receptors, transient receptor potential channels, cyclooxygenase enzymes, and other receptors. Reported reductions in intraocular pressure and antioxidant, anti-inflammatory, anti-tumoral, neuroprotective, appetite-stimulating, and other effects in this research are preclinical findings, not demonstrated human benefits. 4

CBN: sleep findings are from rats

CBN is used in community isolate products and is claimed to have sleep effects comparable to conventional sleep medications. The supplied evidence, however, reports an objective sleep study in rats rather than a controlled human sleep trial. 2

In that animal study, CBN increased total sleep time in rats, with an initial period of sleep suppression followed by a marked increase. It increased both non-rapid eye movement and rapid eye movement sleep. The comparison with zolpidem was also made in rats: CBN’s effect on non-rapid eye movement sleep was comparable in magnitude, while zolpidem did not affect rapid eye movement sleep in the same way. These animal results cannot be presented as evidence that CBN helps people sleep. 2

The same rat research found that 11-hydroxy-CBN, a primary metabolite, reached brain concentrations comparable to CBN and influenced sleep architecture with some differences from CBN itself. The metabolite was active at CB1 receptors with potency and efficacy comparable to Δ9-THC in the study’s experimental testing, whereas CBN itself had much lower activity. This is animal and laboratory evidence about CBN and its metabolite, not evidence of a human effect or a human safety profile. 2

CBC: early evidence without established human efficacy

CBC is structurally and pharmacologically distinct from other cannabinoids despite sharing a common precursor with them. A review describes research examining CBC’s pharmacodynamics, pharmacokinetics, receptor profile, and possible antinociceptive, antibacterial, and anti-seizure activity. The supplied material characterizes the studies as preliminary and calls for further investigation; it does not report a controlled human efficacy result. 3

Claims that CBC may have anti-inflammatory, anticonvulsant, antibacterial, or antinociceptive effects should therefore be treated as preliminary research claims, not established benefits for people. The evidence supplied does not identify which of these possibilities, if any, has been confirmed in adequately controlled human studies. 3

CBC products are described as commercially available over the counter and widely used, with little or no evidence of their safety or efficacy. Commercial availability is not the same as controlled human evidence, and the supplied material does not establish a reliable dose, product quality, or safety profile for CBC products. 3

What these findings do not establish

A finding about CBG cannot be used to support a claim about CBN or CBC. The CBG result comes from a small acute controlled human study; the CBN sleep result comes from rats; and the CBC evidence described here is preliminary research summarized in a review. The differences in evidence type mean that these compounds must be assessed separately rather than described as having a shared set of benefits. 1 2 3

The supplied evidence also does not establish long-term safety for CBG, CBN, or CBC, nor does it establish that retail products contain the same preparation or amount studied in research. Evidence about EPIDIOLEX concerns a cannabidiol medicine used in clinical trials and should not be transferred to CBG, CBN, or CBC. 5 3

A cautious bottom line

CBG has the clearest human signal in the supplied evidence, but it comes from only 34 healthy adults and concerns acute effects under controlled study conditions. 1

CBN has a rat sleep finding and evidence that an active metabolite may contribute to the effect, but the supplied evidence does not establish that CBN improves sleep in humans. 2

CBC remains a preliminary research topic in the supplied evidence, and its commercial availability is accompanied by little or no evidence of safety or efficacy. 3

For any personal use decision, especially alongside other medicines or for a medical symptom, the available evidence is not a substitute for advice from a clinician, pharmacist, or other qualified professional.